Remission of type 2 diabetes: A critical appraisal.
作者信息
Ricci Michele, Mancebo-Sevilla Juan José, Cobos Palacios Lidia, Sanz-Cánovas Jaime, López-Sampalo Almudena, Hernández-Negrin Halbert, Pérez-Velasco Miguel Angel, Pérez-Belmonte Luis M, Bernal-López Maria Rosa, Gómez-Huelgas Ricardo
机构信息
Internal Medicine Clinical Management Unit, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma BIONAND), Malaga, Spain.
Faculty of Medicine, Universidad de Málaga, Malaga, Spain.
出版信息
Front Endocrinol (Lausanne). 2023 Apr 3;14:1125961. doi: 10.3389/fendo.2023.1125961. eCollection 2023.
Abstract
摘要
相似文献
1
Remission of type 2 diabetes: A critical appraisal.
Front Endocrinol (Lausanne). 2023 Apr 3;14:1125961. doi: 10.3389/fendo.2023.1125961. eCollection 2023.
2
Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function.
Diabet Med. 2001 Jan;18(1):10-6. doi: 10.1046/j.1464-5491.2001.00395.x.
3
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.
J Clin Endocrinol Metab. 2020 Aug 1;105(8). doi: 10.1210/clinem/dgaa248.
4
[Is it possible to achieve sustained remission or cure of type 2 diabetes mellitus in the 21st century?].
Ter Arkh. 2017;89(10):4-11. doi: 10.17116/terarkh201789104-11.
5
Beating type 2 diabetes into remission.
BMJ. 2017 Sep 13;358:j4030. doi: 10.1136/bmj.j4030.
6
Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial.
J Clin Endocrinol Metab. 2017 May 1;102(5):1596-1605. doi: 10.1210/jc.2016-3373.
7
Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial.
Transl Res. 2021 Dec;238:12-24. doi: 10.1016/j.trsl.2021.07.001. Epub 2021 Jul 21.
8
The impact of bariatric surgery on insulin-treated type 2 diabetes patients.
Surg Endosc. 2018 Feb;32(2):990-1001. doi: 10.1007/s00464-017-5777-5. Epub 2017 Aug 25.
9
Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal.
Diabetes Metab Syndr. 2019 May-Jun;13(3):1975-1989. doi: 10.1016/j.dsx.2019.04.014. Epub 2019 Apr 25.
10
Intensive insulin therapy in patients with type 2 diabetes.
Lancet. 2008 Aug 30;372(9640):717; author reply 717-8. doi: 10.1016/S0140-6736(08)61302-1.
引用本文的文献
1
HMOX1 as a Novel Biomarker for Glucose-Lipid Metabolism Disorder and T2DM: Systematic Bioinformatics Investigation and Experimental Verification.
ACS Omega. 2025 Apr 16;10(16):16123-16137. doi: 10.1021/acsomega.4c09662. eCollection 2025 Apr 29.
2
Leveraging Co-Design, Design Thinking, and Service Blueprinting to Create Digital Health Behavior Change Innovations: Insights From a Co-Design Workshop With Type 2 Diabetes Remission Health Coaches.
J Diabetes Sci Technol. 2025 Apr 29:19322968251335303. doi: 10.1177/19322968251335303.
3
Nutrition Interventions for Remission of Type 2 Diabetes: Potential Role for Diabetes-Specific Nutrition Formulas.
Clin Diabetes. 2024 Oct 28;43(2):291-302. doi: 10.2337/cd24-0052. eCollection 2025 Spring.
4
Type 2 diabetes in children and adolescents: Exploring the disease heterogeneity and research gaps to optimum management.
World J Clin Pediatr. 2024 Jun 9;13(2):91587. doi: 10.5409/wjcp.v13.i2.91587.
本文引用的文献
1
Remission of Type 2 Diabetes: User's Guide: Diabetes Canada Clinical Practice Guidelines Expert Working Group.
Can J Diabetes. 2022 Dec;46(8):762-774. doi: 10.1016/j.jcjd.2022.10.005. Epub 2022 Nov 11.
2
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus.
Diabetes Metab J. 2022 Mar;46(2):165-180. doi: 10.4093/dmj.2021.0377. Epub 2022 Mar 24.
3
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
Diabetes Care. 2022 Jan 1;45(1):178-185. doi: 10.2337/dc21-0278.
4
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18.
5
Sex differences in intraorgan fat levels and hepatic lipid metabolism: implications for cardiovascular health and remission of type 2 diabetes after dietary weight loss.
Diabetologia. 2022 Jan;65(1):226-233. doi: 10.1007/s00125-021-05583-4. Epub 2021 Oct 16.
6
Consensus report: definition and interpretation of remission in type 2 diabetes.
Diabetologia. 2021 Nov;64(11):2359-2366. doi: 10.1007/s00125-021-05542-z. Epub 2021 Aug 30.
7
Safety of Semaglutide.
Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021.
8
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Defining remission of type 2 diabetes in research studies: A systematic scoping review.
PLoS Med. 2020 Oct 28;17(10):e1003396. doi: 10.1371/journal.pmed.1003396. eCollection 2020 Oct.
Zotero 插件